Sarepta Therapeutics
SRPT
#4401
Rank
S$3.02 B
Marketcap
S$28.85
Share price
-2.45%
Change (1 day)
-82.93%
Change (1 year)
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.

Revenue for Sarepta Therapeutics (SRPT)

Revenue in 2025 (TTM): S$3.18 Billion

According to Sarepta Therapeutics 's latest financial reports the company's current revenue (TTM ) is S$3.12 Billion. In 2024 the company made a revenue of S$2.58 Billion an increase over the revenue in the year 2023 that were of S$1.64 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Sarepta Therapeutics from 1997 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) S$3.18 B23.28%
2024 S$2.58 B57.44%
2023 S$1.64 B31.28%
2022 S$1.25 B31.82%
2021 S$0.94 B32.8%
2020 S$0.71 B39.17%
2019 S$0.51 B24.84%
2018 S$0.41 B98.91%
2017 S$0.20 B2535.24%
2016 S$7.84 M342.66%
2015 S$1.77 M-86.25%
2014 S$12.89 M-28.44%
2013 S$18.01 M-60.54%
2012 S$45.64 M-24.99%
2011 S$60.85 M60.58%
2010 S$37.89 M53.47%
2009 S$24.69 M-18.78%
2008 S$30.4 M92.32%
2007 S$15.8 M8841.65%
2006 S$0.17 M-97.78%
2005 S$7.96 M1034.2%
2004 S$0.7 M-57.38%
2003 S$1.64 M13.49%
2002 S$1.45 M11.08%
2001 S$1.3 M-41.87%
2000 S$2.24 M575.22%
1999 S$0.33 M-49.58%
1998 S$0.66 M30.57%
1997 S$0.5 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Gilead Sciences
GILD
S$37.69 B 1,105.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
S$1.32 B-57.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNA
S$27.04 M-99.14%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
S$0.77 B-75.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
S$4.15 B 32.99%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
S$2.30 B-26.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Insmed
INSM
S$0.57 B-81.48%๐Ÿ‡บ๐Ÿ‡ธ USA